Full Press Release Details
RETRACTABLE TECHNOLOGIES, INC. REPORTS
LITTLE ELM, Texas, March 27, 2026-Retractable
Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further
details concerning the results of operations as well as other matters are available in Retractable's Form 10-K filed on March 27,
2026 with the U.S. Securities and Exchange Commission.
The Company's revenues for 2025 increased
15.8%. The Company's revenues were approximately $38.3 million in 2025 as compared to approximately $33.0 million in the prior
year. Domestic revenues increased 9.7% principally due to an increase in VanishPoint and EasyPoint
needle sales. International revenues increased 64.0% predominantly due to higher EasyPoint needle sales. Comparability
of 2025 to 2020-2023 financial results is challenging due to the unusual volume of pandemic sales in those years.
The Company's operating costs remain high
since its facility expansion and, more recently, an increase in domestic production in connection with 2024-2026 tariffs. Total
operating expenses were $21.2 million in 2025. The 2025 loss from operations was $21.2 million as compared to a loss from operations
of $21.1 million in the prior year.
The net decrease in cash for 2025 was $1.6 million.
At the end of 2025, the Company's cash position was $2.6 million, and the Company held $34.4 million in debt and equity securities.
Approximately $1.8 million was incurred in tariff
expense in 2025. The Company obtained 62.6% of its products from manufacturers in China. As of March 9, 2026, the prevailing
tariff rate on most syringe and needle products imported from China was 120%. As foreign trade policy continues to evolve, uncertainty
as to future tariff rates remains. Management expects that tariffs will continue to have a material impact on the Company's operations
and financial position.
Retractable manufactures and markets VanishPoint
and Patient Safe safety medical products and the EasyPoint needle. The VanishPoint syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint
needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
For more information on Retractable, visit its
website at www.retractable.com.
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
Factors that could cause or contribute to such
differences include, but are not limited to: tariffs; material changes in demand, Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief